Connor, Clark & Lunn Investment Management (CC&L)’s Coherus Oncology CHRS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-88,022	Closed	-$697K	–	1266
2022 Q4	$697K	Buy	+88,022	New	+$677K	﹤0.01%	797
2022 Q3	–	Sell	-48,389	Closed	-$350K	–	1124
2022 Q2	$350K	Sell	48,389 -15,402	-24%	-$134K	﹤0.01%	841
2022 Q1	$824K	Buy	+63,791	New	+$811K	﹤0.01%	697
2021 Q1	–	Sell	-14,211	Closed	-$247K	–	992
2020 Q4	$247K	Sell	14,211 -1,678	-11%	-$29.9K	﹤0.01%	805
2020 Q3	$291K	Sell	15,889 -352	-2%	-$6.55K	﹤0.01%	793
2020 Q2	$290K	Buy	+16,241	New	+$275K	﹤0.01%	848

Other funds holding CHRS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CHRS Position: Q1 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Coherus Oncology (CHRS) in Q1 2023, closing a stake of 88,022 shares — an estimated $697K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CHRS in Q2 2020 and held it in 6 quarters. The position peaked at $824K in Q1 2022. 163 funds tracked by Wall St. Rank hold CHRS as of Q1 2023.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Coherus Oncology position as of Q1 2023 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 88,022 Coherus Oncology shares in Q1 2023, an estimated $697K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Coherus Oncology in Q2 2020 and held it in 6 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Coherus Oncology position peaked at $824K in Q1 2022.
163 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2023, filed 10 May 2023.